Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
1286588-92-8Cl.[2H]C([2H])([2H])C([2H])([2H])NC(C)Cc1ccc2c(c1)OCO2IBDIPBWIXJRJQM-IYSLTCQOSA-N1286588-92-8Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Warning
H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]
P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 39 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Beschreibung3,4-MDEA-d5 (hydrochloride) (exempt preparation) (Item No. 22876) is intended for use as an internal standard for the quantification of 3,4-MDEA (Item Nos. 14085 | ISO60196) by GC- or LC-MS. 3,4-MDEA is categorized as an amphetamine. It has similar psychotropic action to MDMA and shares the common name of "ecstasy". Postmortem findings in human deaths associated with 3,4-MDEA as well as 3,4-MDMA indicate striking brain and myocardial damage as well as liver necrosis. 3,4-MDEA is regulated as a Schedule I compound in the United States. 3,4-MDEA-d5 (hydrochloride) (exempt preparation) (Item No. 22876) is provided as a DEA exempt preparation. This product is intended for research and forensic applications.